Volume 14 Supplement 1

Abstracts from the Combined Northern and Yorkshire Deaneries Rheumatology Annual Conference 2012

Open Access

Soluble molecule profiling and network analysis of primary Sjögren's Syndrome patient serum

  • JR Tarn1,
  • A Natasari1,
  • S Mitchell1,
  • S Bowman2,
  • E Price3,
  • C Pease4,
  • P Emery4,
  • J Andrews4,
  • M Bombardieri5,
  • N Sutcliffe5,
  • C Pitzalis5,
  • P Lanyon6,
  • J McLaren7,
  • J Hunter8,
  • M Gupta8,
  • M Regan9,
  • A Cooper10,
  • I Giles11,
  • D Isenberg11,
  • D Young1,
  • D Lendrem1,
  • C Downie1,
  • H Foggo1,
  • P Stocks1,
  • S Edgar1 and
  • WF Ng1
BMC Musculoskeletal Disorders201314(Suppl 1):A2

DOI: 10.1186/1471-2474-14-S1-A2

Published: 14 February 2013


Primary Sjögren’s Syndrome (pSS) is a chronic autoimmune syndrome characterised by sicca symptoms, fatigue, musculoskeletal pain and an increased risk of lymphoma. Patient populations are notably heterogeneous in their symptoms, adding to the challenge of pSS research. This study utilises serum samples from the UK Primary Sjögren’s Syndrome Registry (UKPSSR) - a large cohort of clinically well-characterised pSS patients and healthy controls with an aim to determine whether serum cytokines, chemokines and adhesion molecules may be used to differentiate pSS patients from healthy controls.


Serum levels of 24 different analytes for 150 pSS patients and 30 age matched healthy controls were measured using Cytometric Bead Array (BD Biosciences).

The primary Sjögren’s Syndrome subjects (characterised by AECG criteria) were stratified as follows:

• Lymphoma and/or paraprotein positive;

• High systemic disease activity (ESSDAI score > 12);

• High Fatigue (VAS score >85);

• Low residual glandular function (OSF <1 ml/15 min and Schirmer’s test <1 cm)

The relationship between the levels of each analyte and clinical and laboratory parameters of PSS was examined using multivariate analysis and Mann-Whitney U testing; p-values were adjusted for multiple comparisons using Bonferroni’s correction.


There were marked differences in the levels of 11 analytes between pSS patients and healthy controls, with a p value <0.001, statistically significant after Bonferroni’s correction for multiple comparisons. However, none of the serum factors measured significantly differentiate different Sjögren’s subsets after multiple comparison correction.

The violin-box plots in Figure 1 show the data distribution. Most soluble molecules show an ‘hour-glass’ distribution, particularly within the patient group corresponding to groups of patients with higher and lower levels of analyte.

Figure 1


Differences in blood cytokine and chemokine levels between primary Sjögren’s Syndrome patients and controls can be detected in serum through the use of Cytometric Bead Arrays. 11 serum analytes differ significantly between patients and controls: IP10 (CXCL10), IL17, IL21, IFNa, MIP1a (CCL3), LTA and TNFa, MIP1b (CCL4), IFNa, MIG (CXCL9), IL6 and IL10. Our observations raise the possibility that these analytes may be important in disease pathogenesis.

Authors’ Affiliations

Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle University
University Hospital Birmingham
Great Western Hospitals NHS Foundation Trust
Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds & NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust
Barts and the London NHS Trust
Nottingham University Hospital
NHS Fife, Whyteman’s Brae Hospital
Gartnavel General Hospital
Royal Derby Hospital
Royal Hampshire County Hospital
University College London Hospitals NHS Foundation Trust


© Tarn et al; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.